Leap therapeutics announces completion of enrollment in part a of the defiance study of dkn-01 for the treatment of colorectal cancer patients

Cambridge, mass. , april 12, 2023 /prnewswire/ -- leap therapeutics, inc. (nasdaq:lptx), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced that enrollment has been completed in part a of the phase 2 defiance study evaluating dkn-01, leap's anti-dickkopf-1 (dkk1) antibody, in combination with standard of care bevacizumab and chemotherapy as a second-line treatment for patients with advanced colorectal cancer (crc).
LPTX Ratings Summary
LPTX Quant Ranking